Prolonged <i>versus</i> standard native <i>E. coli</i> asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.

Exploratory analysis with an a posteriori classification of the ALL patients according to NCI risk criteria showed a trend towards higher 8-year disease-free survival rate for the long-ASNase patients in the NCI standard-risk group due to a lower number of bone marrow relapses.

also in 53,322 other papers